McGill, iSAEC Partner on TB Drug Reactions | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Montreal's McGill University will partner with the International Serious Adverse Events Consortium (iSAEC) to enable studies of the genetic basis of adverse reactions to Tuberculosis treatment.

The iSAEC's International Drug Induced Liver Injury Consortium (IDILIC) currently is recruiting patients with serious liver injuries from drugs and McGill is serving as the coordinating center for an international randomized trial for the treatment of latent TB.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.